MY208416A - Antibody capable of binding to thymic stromal lymphopoietin and use thereof - Google Patents

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Info

Publication number
MY208416A
MY208416A MYPI2021007036A MYPI2021007036A MY208416A MY 208416 A MY208416 A MY 208416A MY PI2021007036 A MYPI2021007036 A MY PI2021007036A MY PI2021007036 A MYPI2021007036 A MY PI2021007036A MY 208416 A MY208416 A MY 208416A
Authority
MY
Malaysia
Prior art keywords
antibody
binding
tslp
thymic stromal
stromal lymphopoietin
Prior art date
Application number
MYPI2021007036A
Inventor
Weikang Tao
Hua Ying
Hu Ge
Tingting Li
Yifang Wang
Guimei Yang
Jinping Shi
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MY208416A publication Critical patent/MY208416A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)

Abstract

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
MYPI2021007036A 2019-06-04 2020-06-03 Antibody capable of binding to thymic stromal lymphopoietin and use thereof MY208416A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910480579 2019-06-04
PCT/CN2020/094154 WO2020244544A1 (en) 2019-06-04 2020-06-03 Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Publications (1)

Publication Number Publication Date
MY208416A true MY208416A (en) 2025-05-08

Family

ID=73652178

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021007036A MY208416A (en) 2019-06-04 2020-06-03 Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Country Status (14)

Country Link
US (3) US12404323B2 (en)
EP (1) EP3981788A4 (en)
JP (3) JP7628966B2 (en)
KR (1) KR20220016897A (en)
CN (2) CN116751295A (en)
AU (1) AU2020286889B2 (en)
BR (1) BR112021024112A2 (en)
CA (1) CA3142545A1 (en)
MX (1) MX2021014804A (en)
MY (1) MY208416A (en)
TW (1) TWI917325B (en)
UA (1) UA130616C2 (en)
WO (1) WO2020244544A1 (en)
ZA (1) ZA202110236B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI917325B (en) 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 Antibodies capable of binding to tslp and the application thereof
MX2023006596A (en) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-tslp antibody pharmaceutical composition and use thereof.
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
TWI915520B (en) * 2021-03-03 2026-02-21 大陸商正大天晴藥業集團股份有限公司 Pharmaceutical compositions comprising anti-tslp antibodies
CN115433275B (en) * 2021-06-02 2026-02-24 启愈生物技术(上海)有限公司 Anti-Thymic Stromal Lymphopoietin (TSLP) antibodies and uses thereof
CN113069543B (en) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 Liquid composition comprising monoclonal antibodies against thymic stromal lymphopoietin
CN113683694B (en) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 Anti-human TSLP monoclonal antibody and application thereof
CN117209604B (en) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 An anti-TSLP monoclonal antibody, its antigen-binding fragment and its application
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024146630A1 (en) * 2023-01-06 2024-07-11 江苏恒瑞医药股份有限公司 Method for treating asthma by using tslp antibody
TW202448501A (en) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 Treatment of chronic rhinosinusitis with anti-tslp antibody
IL323448A (en) * 2023-02-23 2025-12-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Monoclonal antibody preparation targeting TSLP
KR20250167153A (en) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. Anti-stem cell factor (SCF) and anti-thymic stromal lymphopoietin (TSLP) antibodies, and bispecific constructs
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
AR133647A1 (en) 2023-08-25 2025-10-22 Proteologix Us Inc ANTI-IL-13 MULTISPECIFIC ANTIBODY CONSTRUCTS AND THEIR USES
AR134101A1 (en) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd ANTI-TSLP ANTIBODIES AND THEIR USES
TW202529809A (en) 2023-10-17 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Anti-tslp antibody pharmaceutical composition and use thereof
AU2024385129A1 (en) * 2023-11-22 2026-06-11 The United Bio-Technology (Hengqin) Co., Ltd. ANTI-IL-4Rα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND BISPECIFIC ANTIBODY AND USE THEREOF
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
AR135161A1 (en) 2024-01-29 2026-07-08 Astrazeneca Ab COMPOSITIONS OF THYMIC STROMAL LYMPHOPOIETIN-BINDING FRAGMENTS (TSLP) AND METHODS OF USE THEREOF
WO2025214333A1 (en) * 2024-04-08 2025-10-16 江苏恒瑞医药股份有限公司 Method for treating tslp-associated inflammatory disease using anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
CN119431593B (en) * 2024-11-25 2025-11-28 江苏荃信生物医药股份有限公司 Monoclonal antibody against TSLP monoclonal antibody, kit comprising same and detection method using same
WO2026131691A1 (en) 2024-12-16 2026-06-25 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
CN101325968B (en) 2005-03-08 2014-04-23 辉瑞产品公司 Anti-CTLA-4 antibody compositions
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (en) 2006-12-14 2009-04-01 Schering Corp ANTI-TSLP DESIGN ANTIBODY
KR20100034015A (en) 2007-06-20 2010-03-31 아이알엠 엘엘씨 Methods and compositions for treating allergic diseases
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP2010004895A (en) 2009-10-13 2010-01-14 Hiroshima Univ Method for preparation of humanized chicken antibody
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AR091069A1 (en) 2012-05-18 2014-12-30 Amgen Inc PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
CN107428828A (en) 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 TSLP-binding protein
CA2986066A1 (en) 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
CN106474470B (en) 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 Composition of anti-IL-17A antibody
EA038332B1 (en) 2015-09-09 2021-08-10 Новартис Аг Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
CN109206514B (en) * 2017-07-03 2019-10-08 拜西欧斯(北京)生物技术有限公司 TSLP monoclonal antibody and its preparation method and application
CN110538321B (en) 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 CD47 antibody pharmaceutical composition and application thereof
CN109298563A (en) 2018-11-29 2019-02-01 武汉华星光电技术有限公司 A display panel and display device thereof
CN111375059B (en) 2018-12-29 2024-04-16 江苏恒瑞医药股份有限公司 anti-GITR antibody pharmaceutical composition and application thereof
JP7641908B2 (en) 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Pharmaceutical composition containing an antibody against IL-5 and its use
TWI917325B (en) * 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 Antibodies capable of binding to tslp and the application thereof
EP4089111A4 (en) 2020-01-09 2023-10-04 Jiangsu Hengrui Medicine Co., Ltd. NEW POLYPEPTIDE COMPLEX
CR20220457A (en) 2020-02-13 2023-01-09 Amgen Inc HUMAN ANTI-TSLP ANTIBODY FORMULATIONS AND METHODS OF TREATMENT OF AN INFLAMMATORY DISEASE
MX2023006596A (en) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-tslp antibody pharmaceutical composition and use thereof.
WO2023122535A2 (en) * 2021-12-20 2023-06-29 DNARx Nucleic acid expression using subcutaneous administration

Also Published As

Publication number Publication date
BR112021024112A2 (en) 2022-03-22
MX2021014804A (en) 2022-01-18
US20240254215A1 (en) 2024-08-01
CN116751295A (en) 2023-09-15
CN113853387A (en) 2021-12-28
US20260022166A1 (en) 2026-01-22
CN113853387B (en) 2023-04-04
KR20220016897A (en) 2022-02-10
CA3142545A1 (en) 2020-12-10
TW202110882A (en) 2021-03-16
EP3981788A4 (en) 2023-03-22
JP7844685B2 (en) 2026-04-13
AU2020286889A1 (en) 2022-01-20
UA130616C2 (en) 2026-04-01
ZA202110236B (en) 2022-08-31
JP2025066163A (en) 2025-04-22
EP3981788A1 (en) 2022-04-13
US12404323B2 (en) 2025-09-02
US20220340654A1 (en) 2022-10-27
AU2020286889B2 (en) 2026-07-16
JP7628966B2 (en) 2025-02-12
TWI917325B (en) 2026-03-11
US12202891B2 (en) 2025-01-21
JP2022535808A (en) 2022-08-10
WO2020244544A1 (en) 2020-12-10
JP2026108824A (en) 2026-06-30

Similar Documents

Publication Publication Date Title
MX2021014804A (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof.
CO2019007844A2 (en) Novel human transferrin receptor antibody capable of penetrating the blood brain barrier
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2018015393A (en) Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof.
JOP20200309A1 (en) Il-11 antibodies
MX2020007406A (en) PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT OF THE SAME AND PHARMACEUTICAL USE OF THE SAME.
MX2021005396A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof.
AU2018282038A1 (en) Anti TRBC1 antigen binding domains
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
MX2021001143A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof.
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
WO2019121906A9 (en) Fc binding fragments comprising a pd-l1 antigen-binding site
JOP20190002A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MX2023004314A (en) Therapeutic anti-cd40 ligand antibodies.
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
MX2019014375A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof.
UA130540C2 (en) B7-h4 antibody formulations
AR102594A1 (en) ANTI-IL-1b ANTIBODIES AND METHODS OF USE
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MA39821A (en) Binding molecules specific for il-21 and uses thereof
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
WO2022034524A3 (en) Antibodies against ilt2 and use thereof